ARS PharmaceuticalsSPRY
SPRY
About: ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Employees: 160
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 3 (+2) [Q1 2025]
90% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 21
27% more capital invested
Capital invested by funds: $752M [Q4 2024] → $959M (+$207M) [Q1 2025]
11% more funds holding
Funds holding: 165 [Q4 2024] → 183 (+18) [Q1 2025]
4.32% more ownership
Funds ownership: 73.37% [Q4 2024] → 77.69% (+4.32%) [Q1 2025]
7% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 54
41% less call options, than puts
Call options by funds: $2.67M | Put options by funds: $4.54M
Research analyst outlook
We haven’t received any recent analyst ratings for SPRY.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in presentations at the William Blair 45th Annual Growth Stock Conference and 2025 Jefferies Global Healthcare Conference in June.
Neutral
Seeking Alpha
1 month ago
ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Justin Chakma - CBO Richard Lowenthal - Co-Founder, President and CEO Eric Karas - CCO Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Josh Schimmer - Cantor Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Andreas Argyrides - Oppenheimer Louise Chen - Scotiabank Operator Good morning and welcome to ARS Pharmaceuticals' Conference Call. At this time, all participants are in listen-only mode.
Neutral
Zacks Investment Research
1 month ago
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m.
Neutral
GlobeNewsWire
1 month ago
ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as little as $25 (if eligible) in preparation for summer travel and back-to-school SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced neffy ® (epinephrine nasal spray) 1 mg is now available to patients and caregivers by prescription across the U.S. In March 2025, the U.S. Food and Drug Administration approved neffy for the treatment of Type I allergic reactions, including anaphylaxis, in children who are aged four years and older and weigh 15 to < 30 kilograms (33 to < 66 lb.). “Many children fear needles, which can lead parents to delay administering needle-based epinephrine treatments.
Neutral
GlobeNewsWire
1 month ago
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m.
Neutral
GlobeNewsWire
1 month ago
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States
Positive
Seeking Alpha
1 month ago
ARS Pharmaceuticals Has A Blockbuster Candidate
ARS Pharmaceuticals has a recently launched needle-free epinephrine product for allergic reactions, neffy, and strong cash reserves. The company targets a ~$3B+ U.S. market, geographic expansion and intends to also address acute flares in chronic spontaneous urticaria. Financial projections include $500M peak U.S. sales, $500M outside the U.S., and $150M for chronic spontaneous urticaria, with profitability expected by 2027.
Positive
Seeking Alpha
2 months ago
ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await
ARS Pharmaceuticals, Inc.'s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy's competitive edge lies in its innovative intranasal delivery, targeting a $3 billion initial addressable market in the U.S. with potential growth prospects. Despite neffy's potential, risks include competition, pricing pressures, and single-asset dependency, leading to a "Hold" recommendation due to commercial uncertainties.
Neutral
Seeking Alpha
2 months ago
ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President and CEO Eric Karas - Chief Commercial Office Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Alexa Deemer - Cantor Fitzgerald Louise Chen - Scotia Bank Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Julian Harrison - BTIG Operator Good day, and welcome to ARS Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.
Charts implemented using Lightweight Charts™